300194.SZ
Fuan Pharmaceutical (Group) Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 3.91
−0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.7B | 2.4B | 2.6B | 2.4B |
| Cost of Revenue | 1.1B | 1.1B | 1.1B | 1.2B | 1.0B |
| Gross Profit | 617.4M | 642.6M | 1.3B | 1.4B | 1.4B |
| Operating Expenses | |||||
| R&D Expense | 130.4M | 134.7M | 153.2M | 148.8M | 142.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 214.1M | 219.6M | 258.8M | 242.3M | 244.8M |
| Selling & Marketing Expense | 185.8M | 195.1M | 563.4M | 807.1M | 881.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 554.3M | 568.3M | 999.2M | 1.2B | 1.3B |
| Cost and Expenses | 1.6B | 1.7B | 2.1B | 2.5B | 2.3B |
| Operating Income (EBIT) | 70.2M | 84.2M | 320.8M | 298.5M | 178.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 69.7M | 83.2M | 312.2M | 290.4M | 189.4M |
| Income Tax Expense | 7.2M | 6.8M | 34.0M | 55.9M | (11.5M) |
| Bottom Line | |||||
| Net Income | 62.9M | 77.0M | 279.8M | 231.9M | 204.6M |
| Earnings from Cont. Ops | 62.5M | 76.5M | 278.2M | 234.4M | 200.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 62.9M | 77.0M | 279.8M | 231.9M | 204.6M |
| Per Share | |||||
| Basic EPS | CN¥0.06 | CN¥0.06 | CN¥0.24 | CN¥0.19 | CN¥0.17 |
| Diluted EPS | CN¥0.06 | CN¥0.06 | CN¥0.24 | CN¥0.19 | CN¥0.17 |
| Revenue Per Share | CN¥1.53 | CN¥1.35 | CN¥2.05 | CN¥2.17 | CN¥2.01 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.3B | 1.2B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.1B | 1.3B | 1.2B | 1.2B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | — | 289.6M | 518.9M | 507.6M | 363.4M |
| D&A | — | 205.4M | 198.0M | 209.1M | 184.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026